Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers

Journal of the National Cancer Institute

Volumn 88, Issue 20, 1996, Pages 1456-1466

  Hayes, Daniel F ^a,k   Bast, Robert C ^b   Desch, Christopher E ^c   Fritsche Jr , Herbert ^b   Kemeny, Nancy E ^d   Jessup, J Milburn ^e   Locker, Gershon Y ^f   Macdonald, John S ^g   Mennel, Robert G ^h   Norton, Larry ^d   Ravdin, Peter ⁱ   Taube, Sheila ^j   Winn, Rodger J ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f EVANSTON HOSPITAL   (United States)

^g TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

^h TEXAS ONCOLOGY   (United States)

ⁱ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

^k GEORGETOWN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HUMAN; PRACTICE GUIDELINE; RATING SCALE; STANDARD; TREATMENT OUTCOME;

CLINICAL MEDICINE; COSTS AND COST ANALYSIS; HUMANS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 10244261646     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.20.1456     Document Type: Article

References (65)

1. Hayes DF. Tumor markers for breast cancer. Ann Oncol 1993;4:807-19.
2. Simon R. Design and conduct of clinical trials. In: De Vita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 4th ed. Philadelphia: Lippincott, 1993:418-40.
3. Lin DY, Fischl MA. Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials [see comment citation in Medline]. Stat Med 1993;12:835-42.
4. Hillis A, Seigel D. Surrogate endpoints in clinical trials: ophthalmologic disorders. Stat Med 1989;8:427-30.
5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
6. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
7. Hayes DF, Cirrincione C, Camey W, Rodrigue S, Berry D, Younger J, et al. Elevated circulating HER-2/neu related protein (NRP) is associated with poor survival in patients with metastatic breast cancer [abstract]. Proc ASCO 1993;12:58a.
8. Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton BC, Demers L, et al. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 1992;10:1436-43.
9. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995;13:1129-35.
10. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994;54:16-20.
11. Lupu R, Lippman ME, William L. McGuire Memorial Symposium. The role of erbB2 signal transduction pathways in human breast cancer. Breast Cancer Res Treat 1993;27:83-93.
12. Frebourg T, Kassel J, Lam KT, Gryka MA, Barbier N, Andersen TI, et al. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. Proc Natl Acad Sci USA 1992;89:6413-7.
13. Thor AD, Yandell DW. Prognostic significance of p53 overexpression in node-negative breast carcinoma: preliminary studies support cautious optimism [editorial] [see comment citation in Medline]. J Natl Cancer Inst 1993;85:176-7.
14. Carney WP, Hamer PJ, Petit D, Retos C, Greene R, Zabrecky JR, et al. Detection and quantitation of the human neu oncoprotein. J Tumor Marker Oncol 1991;6:53-72.
15. Taylor CR. An exaltation of experts: concerted efforts in the standardization of immunohistochemistry. Hum Pathol 1994;25:2-11.
16. Hayes DF, Mesa-Tejada R, Papsidero L, Croghan G, Korzun A, Norton L, et al. Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. J Clin Oncol 1991;9:1113-23.
17. McClelland RA, Berger U, Miller LS, Powles TJ, Coombes RC. Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy. J Clin Oncol 1986;4:1171-6.
18. Clark GM, Dressier LG, Owens MA, Pounds G, Oldaker T, McGuire WL. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989;320:627-33.
19. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology [editorial]. Br J Cancer 1994;69:979-85.
20. George SL. Statistical considerations and modeling of clinical utility of tumor markers. In: Hayes DF, editor. Hematology/Oncology Clinics of North America: tumor markers in adult solid malignancies. Philadelphia: Saunders, 1994;457-70.
21. Bromley CM, Palechek PL, Benda JA. Preservation of estrogen receptor in paraffin sections. J Histotechnol 1994;17:115-8.
22. American Society of Clinical Oncology Outcomes Working Group. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996;14:671-9.
23. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually [see comment citations in Medline]. J Natl Cancer Inst 1989;81:1879-86.
24. Garber JE. Markers of risk for human malignancies. In: Hayes DF, editor. Hematology/oncology clinics of North America: tumor markers in adult solid malignancies. Philadelphia: Saunders, 1994;471-83.
25. Hayes DF. What are tumor markers, and when should they be used? In: American Society of Clinical Oncology. Educational book: 30th annual meeting. Dallas: American Society of Clinical Oncology, 1994;138-49.
26. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer [see comment citations in Medline]. N Engl J Med 1992;326:1756-61.
27. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors [prior annotation incorrect]. N Engl J Med 1989;320:479-84.
28. Fisher B, Redmond C, Dimitrov NV, Bowman D, Legault-Poisson S, Wickerham DL, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors [prior annotation incorrect]. N Engl J Med 1989;320:473-8.
29. Early Breast Cancer Trialists' Collaborative Group T. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 wornen. Lancet 1992;339:1-15, 71-85.
30. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978;8:283-98.
31. Hanley JA, McNeil BJ. The meaning and use of the area under a Receiver Operating Characteristic (ROC) curve. Diag Radiol 1982;143:29-36.
32. Ingelfinger JA, Mosteller F, Thibodeau LA, Ware JH, editors. Biostatistics in clinical medicine. New York: Macmillan, 1987.
33. Thor AD, Moore DH 2d, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-55.
34. Gelber RD, Goldhirsch A, Hurny C, Bernhard J, Simes RJ. Quality of life in clinical trials of adjuvant therapies. International Breast Cancer Study Group (formerly Ludwig Group). Monogr Natl Cancer Inst 1992;11:127-35.
35. Donovan K, Sanson-Fisher RW, Redman S. Measuring quality of life in cancer patients. J Clin Oncol 1989;7:959-68.
36. Porzsolt F, Tannock I. Goals of palliative cancer therapy. J Clin Oncol 1993;11:378-81.
37. Robertson JF, Ellis IO, Bell J, Todd JH, Robins A, Elston CW, et al. Carcinoembryonic antigen immunocytochemistry in primary breast cancer. Cancer 1989;64:1638-45.
38. Slebos RJ, Evers SG, Wagenaar SS, Rodenhuis S. Cellular protooncogenes are infrequently amplified in untreated non-small cell lung cancer. Br J Cancer 1989;59:76-80.
39. Sandler AB, Buzaid AC. Lung cancer: a review of current therapeutic modalities. Lung 1992;170:249-65.
40. Jaklitsch MT, Strauss GM, Sugarbaker DJ, Neoadjuvant and adjuvant therapy in the management of locally advanced non-small-cell lung cancer. World J Surg 1993;17:729-34.
41. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994;266:120-2.
42. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
43. National Advisory Council for Human Genome Research. Statement on use of DNA testing for presymptomatic identification of cancer risk. JAMA 1994;271:785.
44. Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: implications for presymptomatic testing and screening. JAMA 1995;273:535-41.
45. Strauss GM, Skarin AT. Use of tumor markers in lung cancer. In: Hayes DF, editor. Hematology/Oncology Clinics of North America: tumor markers in adult solid malignancies. Philadelphia: Saunders, 1994:507-32.
46. Kemeny M, Sugarbaker P, Smith T, Edwards B, Shawker T, Vermess M, et al. A prospective analysis of laboratory tests and imaging to detect hepatic lesions. Ann Surg 1982;195:163-7.
47. Tondini C, Hayes DF, Kufe D. Circulating tumor markers in breast cancer. In: Henderson IC, editor. Diagnosis and therapy of breast cancer. Philadelphia: Saunders, 1989:653-74.
48. Steele G Jr, Ellenberg S, Ramming K, O'Connell M, Moertel C, Lessner H, et al. CEA monitoring among patients in multi-institutional adjuvant G.I. therapy protocols. Ann Surg 1982;196:162-9.
49. Minton JP, Hoehn JL, Gerber DM, Horsley JS, Connolly DP, Salwan F, et al. Results of a 400-patient carcinoembryonic antigen second-look coloretal cancer study. Cancer 1985;55:1284-90.
50. Martin EW Jr, Cooperman M, King G, Rinker L, Carey LC, Minton JP. A retrospective and prospective study of serial CEA determinations in the early detection of recurrent colon cancer. Am J Surg 1979;137:167-9.
51. Hayes DF, Kaplan W, Evaluation of patients after primary therapy. In: Harris J, Lippman M, Morrow M, Hellman S, editors. Diseases of the breast. Philadelphia: Lippincott, 1996:627-45.
52. Bartlett NL, Freiha FS, Torti FM. Serum markers in germ cell neoplasms. Hematol Oncol Clin North Am 1991;5:1245-60.
53. Bosl GJ, Head MD. Serum tumor marker half-life during chemotherapy in patients with germ cell tumors. Int J Biol Markers 1994;9:25-8.
54. Klein EA. Tumor markers in testis cancer. Urol Clin North Am 1993; 20:67-73.
55. Woolf SH. Practice guidelines: a new reality in medicine. II. Methods of developing guidelines. Arch Intern Med 1992;152:946-52.
56. Tunis SR, Hayward RSA, Wilson MC, Rubin HR, Bass EB, Johnston M, et al. Internists' attitudes about clinical practice guidelines [see comment citations in Medline]. Ann Intern Med 1994;120:956-63.
57. Kaluzny AD, Rimer B, Harris R. The National Cancer Institute and guideline development: lessons from the breast cancer screening controversy. J Natl Cancer Inst 1994;86:901-3.
58. Browman GP, Levine MN, Mohide EA, Hayward RS, Pritchard KI, Gafni A, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995; 13:502-12.
59. Canadian Task Force on the Periodic Health Examination. The periodic health examination. Can Med Assoc J 1979;121:1193-254.
60. Levine MN, Browman GP, Gent M, Roberts R, Goodyear M. When is a prognostic factor useful? A guide for the perplexed. J Clin Oncol 1991; 9:348-56.
61. Burke HB, Henson DE. The American Joint Committee on Cancer. Criteria for prognostic factors and for an enhanced prognostic system. Cancer 1993;72:3131-5.
62. Burke HB. Artificial neural networks for cancer research: outcome prediction. Semin Surg Oncol 1994;10:73-9.
63. Ravdin PM, Clark GM, Hilsenbeck SG, Owens MA, Vendely P, Pandian MR, et al. A demonstration that breast cancer recurrence can be predicted by neural network analysis. Breast Cancer Res Treat 1992;21:47-53.
64. Ravdin PM, Clark GM, Hough JJ, Owens MA, McGuire WL. Neural Network Analysis of DNA flow cytometry histograms. Cytometry 1993;14:74-80.
65. Clark GM, Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, et al. How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer 1993; 71(6 Suppl):2157-62.